-+ 0.00%
-+ 0.00%
-+ 0.00%

Corbus to present updated Phase 1/2 CRB-701 data at ASCO 2026

PUBT·04/22/2026 12:05:17
Listen to the news
Corbus to present updated Phase 1/2 CRB-701 data at ASCO 2026
  • Corbus outlined updated Phase 1/2 clinical data for Nectin-4 antibody-drug conjugate CRB-701 in recurrent or metastatic head and neck squamous cell carcinoma, cervical cancer.
  • Results were previously presented at ESMO 2025, including dose-optimization findings that indicated encouraging efficacy, safety.
  • Fresh updates will be presented at ASCO 2026, with focus on response durability plus subgroup analysis in head and neck cancer.
  • Corbus expects to start registrational study for CRB-701 in second-line head and neck cancer in mid-2026.
  • Company also plans to report CRB-701 combination data with Keytruda in first-line head and neck cancer in Q4 2026 to support potential registration-enabling trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220800PRIMZONEFULLFEED9694522) on April 22, 2026, and is solely responsible for the information contained therein.